BeStock  
Stocks › Biotechnology › GLUE

Monte Rosa Therapeutics GLUE

US equityMarket cap rank #3343Biotechnology
$10.17 +$0.30 (+3.04%)
Pre-market · Oct 8, 7:50 am ET · After hours $10.00 -1.67%
Open$9.84
Prev close$9.87
Day range$9.68 – $10.75
Volume2.08M
Market cap$867.64M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership115.9%-2.56 pts vs. prior quarter
Institutions holding228-4 vs. prior quarter
Insider trades (recent)12 buys / 35 sellsNet selling
Short interest22.58% of floatDays to cover 17.1 · as of 15 Sep 2026
Short-sale volume share16.7%5-day average of daily volume

Short-sale volume as % of daily volume

10%14%18%22%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.27M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

+$110.6KSuper−$1.4MBig−$3.0MMid−$3.3MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 38.3% of shares outstanding.

Largest holders

  • T. Rowe Price Group, Inc.10.39%
  • BlackRock8.02%
  • New Enterprise Associates, Inc.7.84%
  • Dimension Capital Partners, LLC6.64%
  • TCG Crossover Management, LLC5.42%
  • Vestal Point Capital, LP5.39%
  • BVF Partners L.P.5.23%
  • Baker Bros. Advisors LP5.09%

By investor type

  • Mutual Fund48.02%
  • Hedge Fund39.67%
  • VC/PE Fund23.89%
  • Public Company2.64%
  • Private Company0.84%
  • Individual/Insider0.53%
  • Family Office/Trust0.37%
  • Government Pension Fund0.28%

Reported short interest has risen from 22.06% to 22.58% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +2,140,983 10.4%
BlackRock Mutual Fund 2026/Q3 +1,205,403 8.0%
Vestal Point Capital, LP Hedge Fund 2026/Q3 +996,535 5.4%
Woodline Partners LP Hedge Fund 2026/Q3 +888,388 1.1%
Opaleye Management Inc. Hedge Fund 2026/Q3 +745,000 0.9%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +647,796 0.8%
Boone Capital Management LLC Hedge Fund 2026/Q3 +615,287 0.7%
Nextech Invest Ltd. VC/PE Fund 2026/Q3 +456,916 0.9%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +411,104 4.6%
Janus Henderson Group plc Mutual Fund 2026/Q3 +386,568 1.3%
State Street Global Advisors Mutual Fund 2026/Q3 +377,436 4.4%
Kennedy Capital Management LLC Mutual Fund 2026/Q3 +373,552 0.5%
Columbia Management Investment Advisers, LLC Mutual Fund 2026/Q3 +347,338 0.4%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +323,301 2.2%
Duquesne Family Office LLC Family Office/Trust 2026/Q3 +297,600 0.3%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
15 Jul 2026 Markus Warmuth Chief Executive Officer Open Market Disposition -9,500 $23.18 399,038
14 Jul 2026 Jennifer Champoux Chief People & Operations Officer Derivative Exercise and Sale -4,351 $23.38 4,871
5 Jul 2026 Sharon Townson Chief Technology Officer Derivative Exercise and Sale -6,000 $24.13 5,845
30 Jun 2026 New Enterprise Associates, Inc. Other Acquisition +15,000 – 6,692,298
30 Jun 2026 New Enterprise Associates, Inc. Other Disposition -1,015,000 – 6,692,298
29 Jun 2026 Filip Janku Chief Medical Officer Derivative Exercise and Sale -5,407 $24.50 2,612
28 Jun 2026 Anthony Manning Director Derivative Exercise and Sale -10,000 $23.11 –
28 Jun 2026 Filip Janku Chief Medical Officer Derivative Exercise and Sale -6,000 $22.95 1,992
23 Jun 2026 Filip Janku Chief Medical Officer Intent to Sell (Form 144) -30,000 $20.71 –
23 Jun 2026 Filip Janku Chief Medical Officer Derivative Exercise and Sale -36,000 $21.42 1,992
22 Jun 2026 Filip Janku Chief Medical Officer Automatic Disposition -5,845 $20.22 1,992
22 Jun 2026 Sharon Townson Chief Technology Officer Derivative Exercise and Sale -3,000 $20.00 5,845
22 Jun 2026 Jennifer Champoux Chief People & Operations Officer Derivative Exercise and Sale -2,175 $20.00 4,871
16 Jun 2026 Sharon Townson Chief Technology Officer Derivative Exercise and Sale -3,000 $19.00 5,845
16 Jun 2026 Jennifer Champoux Chief People & Operations Officer Derivative Exercise and Sale -2,176 $19.00 4,871
10 Jun 2026 Christine Siu Independent Director Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Andrew Schiff Independent Chairperson Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Anthony Manning Director Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Jan Skvarka Independent Director Other Derivative Acquisition +25,800 $17.10 25,800
10 Jun 2026 Kimberly Blackwell Independent Director & Member of Scientific Advisory Board Other Derivative Acquisition +25,800 $17.10 25,800

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 19,265,990 22.6% 17.1
31 Aug 2026 18,075,786 21.2% 16.6
14 Aug 2026 17,457,317 20.5% 14.0
31 Jul 2026 16,458,543 19.5% 10.6
15 Jul 2026 17,195,471 20.4% 13.1
30 Jun 2026 18,634,735 22.1% 8.5

Discussion

No comments yet — be the first to weigh in on GLUE.

Leave a comment

Scroll to Top